FDA biologics chief outlines ways to remove barriers to cell and gene therapies
At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level. Read More
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders. Read More
Panel to focus on pluripotent stem cells at Cell & Gene Meeting on the Mesa
A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies. Read More
Gene therapy one step closer to delivery across blood-brain barrier: study
Brigham and Women’s Hospital researchers say the rational design of adeno-associated viruses has generated gene therapy delivery vectors that are better at crossing the blood-brain barrier to treat diseases of the central nervous system. Read More
6 startups to compete for $250K grand prize at 2022 BioTools Innovator capstone event
BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa. Read More
Meeting on the Mesa comes at pivotal time for cell and gene therapy industry
Stakeholders from around the cell and gene therapy sector will come together during the Alliance for Regenerative Medicine’s hybrid 2022 Meeting on the Mesa, October 11-13 in Carlsbad, CA, to discuss the opportunities and challenges facing the industry. Read More
FDA creates “Super Office” to manage growing cell and gene therapy workload
The U.S. Food and Drug Administration (FDA) has elevated and reorganized its Office of Tissues and Advanced Therapies to a “Super Office” within the Center of Biologics Research and Evaluation to meet its growing cell and gene therapy workload. Read More
Mixed bag so far in 2022 for cell and gene therapy sector: ARM report
So far, 2022 has been a mixed bag for the cell and gene therapy sector on the regulatory and investment fronts, according to a new report from the Alliance for Regenerative Medicine (ARM). Read More
Biotech licenses drug discovery platform from Harvard, Tufts to study complex CNS diseases
Unravel Biosciences has licensed a drug discovery platform from Harvard University and Tufts University to decode and model complex central nervous system (CNS) diseases. Read More
CRISPR edited rat embryos reveal cause of rare pediatric neurodegenerative disease
Using CRISPR gene editing technology on rat embryos, University of Wisconsin-Madison researchers have revealed the mutation that is responsible for progressive gait abnormalities and other symptoms in human infants and young children with a rare neurodegenerative disease. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
